Compositions that treat or inhibit pathological conditions associated with inflammatory response
A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivatives or conjugates thereof.
1. An anti-inflammatory composition comprising anti-inflammatory effective amounts of a first component selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, dihydro-isoadhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-isoadhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-isoadhumulone; and as a second component, at least one member selected from the group consisting of rosemary, an extract derived from rosemary, a compound derived from rosemary, and a triterpene species.
2. The composition of claim 1 , wherein the first component is derived from hops.
3. The composition of claim 1 , wherein the compound derived from rosemary is selected from the group consisting of 1,8-cineole, 19-alpha-hydroxyursolic acid, 2-β-hydroxyoleanolic acid, 3-O-acetyloleanolic acid, 3-O-acetylursolic acid, 6-methoxy-luteolin-7-glucoside, 6-methoxyluteolin, 6-methoxyluteolin-7-glucoside, methoxyluteolin-7-methylether, 7-ethoxy-rosmanol, 7-methoxy-rosmanol, alpha-amyrin, alpha-humulene, alpha-hydroxyhydrocaffeic acid, alpha-pinene, alpha-terpinene, alpha-terpinenyl acetate, alpha-terpineol, alpha-thujone, apigenin, apigenin-7-glucoside, curcumene, benzyl-alcohol, β-amyrenone, β-amyrin, β-elemene, β-pinene, betulin, betulinic acid, borneol, bornyl-acetate, caffeic acid, camphene, camphor, carnosic acid, carnosol, carvacrol, carvone, caryophyllene, caryophyllene-oxide, chlorogenic acid, diosmetin, gamma-terpinene, hesperidin, isoborneol, limonene, luteolin, luteolin-3′-O-(3″-O-acetyl)-β-D-glucuronide, luteolin-3′-O-(4″-O-acetyl)-β-D-glucuronide, luteolin-3′-O-β-D-glucuronide, luteolin-7-glucoside, methyl-eugenol, myrcene, neo-chlorogenic acid, nepetin, octanoic acid, oleanolic acid, p-cymene, piperitenone, rosmanol, rosmaric acid, rosmaricine, rosmaridiphenol, rosemarinic acid, rosmarinol, rosmariquinone, sabinene, sabinyl acetate, salicylates, salicylic acid-2-β-D-glucoside, squalene, terpinen-4-ol, terpinolene, thymol, trans-anethole, trans-carveol, ursolic acid, verbenone, and zingiberene.
4. The composition of claim 1 , wherein the triterpene species is selected from the group consisting of 18-a-glycyrrhetinic acid, 18-β-glycyrrhetinic acid, 2-a-3-a-dihydrooxyurs-12-3n-28-onic acid, 3-a-hydroxyursolic acid, 3-oxo-ursolic acid, betulin, betulinic acid, celastrol, eburicoic acid, friedelin, glycyrrhizin, gypsogenin, oleanolic acid, oleanolic acid-3-acetate, pachymic acid, pinicolic acid, sophoradiol, soyasapogenol A, soyasapogenol B, tripteris, triptophenolide, tumulosic acid, ursolic acid, ursolic acid-3-acetate, uvaol, and β-sitosterol.
5. The composition of claim 1 , wherein the composition comprises about 0.5 to 10,000 mg of the first component.
6. The composition of claim 1 , wherein the composition comprises about 0.5 to 5,000 mg of the second component, and wherein the second component is selected from the group consisting of rosemary, an extract derived from rosemary, and a compound derived from rosemary.
7. The composition of claim 1 , wherein the composition comprises about 0.035 to 3,500 mg of the triterpene species.
8. The composition of claim 1 , wherein the composition comprises about 0.001 to 10 weight percent of the first component.
9. The composition of claim 1 , wherein the composition comprises about 0.001 to 10 weight percent of the second component.
10. The composition of claim 1 , wherein a ratio of the first component to the second component is in the range of about 100:1 to about 1:100.
11. The composition of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.
12. The composition of claim 1 , further comprising glucosamine.